Keytruda - HealthQuill

The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can be administered under the skin for adults.

US approves Merck’s skin injectable version of cancer drug Keytruda

The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can.

by HealthQuill
September 20, 2025
0 Comments

Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.'s antibody-drug conjugate, cut the risk of an aggressive breast cancer advancement and death by 35% during an end-stage trial.

Drugs Health Pharma

Merck, Gilead’s drug for breast cancer cuts progression risk by 35 per cent

HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.

by HealthQuill
June 1, 2025
0 Comments

Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of overall survival in patients previously treated for a type of metastatic colorectal cancer.

Drugs Health Pharma

Merck’s trial drug combination for colorectal cancer fails main goal

Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.

by HealthQuill
September 25, 2024
0 Comments

Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug Administration.

Drugs Health Pharma

Merck’s advanced lung cancer drug gets US drug regulator’s nod

Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug.

by HealthQuill
September 19, 2024
0 Comments

Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment of Merck & Co.

Drugs Health Pharma

Roche ends small cell lung cancer trials as results show ‘reduced efficacy’

Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.

by HealthQuill
July 4, 2024
0 Comments

Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or melanoma.

Drugs Health Pharma

Moderna, Merck’s skin cancer vaccine shows rise in survival rates

Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or.

by HealthQuill
June 4, 2024
0 Comments

The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.

Drugs Medical Pharma

Merck discontinues trial for combo cancer drug for melanoma

HQ Team May 13, 2024: Merck has discontinued another cancer experimental immunotherapy treatment in patients with a severe form of melanoma due to.

by HealthQuill
May 13, 2024
0 Comments

Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received Breakthrough Therapy Designation from the USFDA.

Drugs Health Pharma

Merck’s end-stage trials of endometrial cancer therapy fail to meet goals

HQ Team May 9, 2024: Merck announced that its Phase 3 trial evaluating Keytruda therapy in combination with chemotherapy, with or without radiotherapy,.